Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 20:36:35时区推断·⟳ 抓取 20:37:20·⚡ 决策 07-29 20:39:04 +1m44s·90.3 天前
英矽智能ISM6331获FDA快速通道资格用于间皮瘤
FDA快速通道资格有助于ISM6331后续与FDA沟通并可能获得滚动审评等便利，但该项目仍处Phase I，尚无可验证疗效和商业化收入。
📄 原文Investing.com↗ 原文
Insilico gets FDA fast track status for mesothelioma drug
S. Korea’s KOSPI rebounds to close 6% in red; SK Hynix drops 10% CAMBRIDGE, Mass. - Insilico Medicine (HKEX:3696) annou…
不做 英矽智能（03696.HK）
快速通道是正面监管进展，但ISM6331仍处Phase I、无疗效或收入增量，且同一管线近期已有ESMO口头报告预热，次日追高缺少正期望。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 英矽智能此前已披露ISM6331获得FDA孤儿药认定和IND批件，说明该项目临床推进并非全新信息。
- ISM6331全球多中心Phase I首例患者给药，项目已进入人体试验阶段。
- 公司公告ISM6331 Phase I首次人体数据被ESMO 2026接收为口头报告，已提前强化市场对该管线的关注。市场反应:3696.HK在7月27日收报47.76港元，较前收涨约1.49%。
- Investing.com转述ISM6331获FDA快速通道资格，是本次新增事件的主要公开扩散节点。市场反应:事件发生时港股已收盘，无法连续成交。
关键理由
- FDA快速通道资格有助于ISM6331后续与FDA沟通并可能获得滚动审评等便利，但该项目仍处Phase I，尚无可验证疗效和商业化收入。
- ISM6331在2024年已获孤儿药资格、2025年已启动全球Phase I，7月27日又公告ESMO 2026口头报告，本次更像临床开发进展叠加而非终局批准。
- 公司最新可见市值约276亿港元，间皮瘤适应症患者基数小，当前事件无法量化短期收入/利润增量。
主要风险
- 若ESMO 2026披露的Phase I数据显著优于同类TEAD项目，后续可能形成新的、比本次快速通道更硬的临床数据催化。
- 港股次日开盘可能因新股和AI制药标签出现情绪跳空，但缺少疗效数据时追高容易见光死。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-02-17 · 影响 weakens
项目仍处Phase I剂量探索阶段，ClinicalTrials.gov未显示注册性疗效结果或批准上市信息。
检索:ISM6331 Phase I Fast Track no clinical efficacy data mesothelioma 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-27 · 影响 weakens
同一管线两天前已有ESMO口头报告催化，降低本次快速通道作为单独新增预期差的力度。
检索:ISM6331 ESMO 2026 oral presentation Insilico July 27 2026 原文 ↗
原文全文
展开原文 · 2,117 字
S. Korea’s KOSPI rebounds to close 6% in red; SK Hynix drops 10%
CAMBRIDGE, Mass. - Insilico Medicine (HKEX:3696) announced today that its drug candidate ISM6331 received Fast Track Designation from the U.S. Food and Drug Administration for treating adult patients with unresectable malignant pleural mesothelioma whose disease progressed after prior treatment with anti-PD-1 antibody therapy, with or without anti-CTLA-4 antibody therapy, and platinum-based chemotherapy.
ISM6331 is a pan-TEAD inhibitor developed using the company’s Chemistry42 platform. The designation marks the first Fast Track Designation for a program in Insilico’s pipeline, according to a press release statement.
The Fast Track Designation provides ISM6331 with enhanced FDA engagement, including more frequent meetings and written feedback on clinical trial design, biomarker strategies, and development plans. The program may also qualify for Accelerated Approval, Priority Review, and Rolling Review if relevant criteria are met.
ISM6331 previously received Orphan Drug Designation from the FDA for mesothelioma treatment in June 2024. The first patient was dosed in the global multicenter Phase I trial of ISM6331 in January 2025.
"Receiving Fast Track Designation validates the strong clinical potential of ISM6331," said Halle Zhang, Vice President of Clinical Development for Oncology at Insilico Medicine.
The drug candidate was nominated in June 2023 and developed through structure-based drug design strategies. Initial Phase I first-in-human clinical data has been accepted for presentation at the ESMO 2026 Congress.
Insilico Medicine is a clinical-stage biotechnology company that uses artificial intelligence for drug discovery. The company was listed on the Hong Kong Stock Exchange on December 30, 2025. Investors tracking this newly-public biotech can access comprehensive financial metrics and analysis through InvestingPro, which offers real-time data and expert insights for emerging pharmaceutical companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
CAMBRIDGE, Mass. - Insilico Medicine (HKEX:3696) announced today that its drug candidate ISM6331 received Fast Track Designation from the U.S. Food and Drug Administration for treating adult patients with unresectable malignant pleural mesothelioma whose disease progressed after prior treatment with anti-PD-1 antibody therapy, with or without anti-CTLA-4 antibody therapy, and platinum-based chemotherapy.
ISM6331 is a pan-TEAD inhibitor developed using the company’s Chemistry42 platform. The designation marks the first Fast Track Designation for a program in Insilico’s pipeline, according to a press release statement.
The Fast Track Designation provides ISM6331 with enhanced FDA engagement, including more frequent meetings and written feedback on clinical trial design, biomarker strategies, and development plans. The program may also qualify for Accelerated Approval, Priority Review, and Rolling Review if relevant criteria are met.
ISM6331 previously received Orphan Drug Designation from the FDA for mesothelioma treatment in June 2024. The first patient was dosed in the global multicenter Phase I trial of ISM6331 in January 2025.
"Receiving Fast Track Designation validates the strong clinical potential of ISM6331," said Halle Zhang, Vice President of Clinical Development for Oncology at Insilico Medicine.
The drug candidate was nominated in June 2023 and developed through structure-based drug design strategies. Initial Phase I first-in-human clinical data has been accepted for presentation at the ESMO 2026 Congress.
Insilico Medicine is a clinical-stage biotechnology company that uses artificial intelligence for drug discovery. The company was listed on the Hong Kong Stock Exchange on December 30, 2025. Investors tracking this newly-public biotech can access comprehensive financial metrics and analysis through InvestingPro, which offers real-time data and expert insights for emerging pharmaceutical companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。